Literature DB >> 8543744

Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy.

G Hedlin1, H Heilborn, G Lilja, K Norrlind, K O Pegelow, C Schou, H Løwenstein.   

Abstract

BACKGROUND: A 5-year follow-up study was conducted to investigate the duration of the effects of a 3-year course of immunotherapy with standardized cat or dog extracts in 32 children and adults with asthma caused by animal dander.
METHODS: Thirty of the subjects could be reached with a questionnaire, 19 underwent bronchial allergen and histamine challenges, and four had only a histamine challenge. Specific IgE and IgG4 levels in serum were measured in those who underwent challenges.
RESULTS: Almost all subjects (26 of 30) reported no change (17 subjects) or increased tolerance (9 subjects) on exposure to cats or dogs. In contrast, 17 of the 19 who underwent allergen challenges had increased allergen sensitivity compared with when therapy was stopped (p < 0.01), and the results were no longer significantly different from before therapy was started. Mean provocative concentration of histamine causing a 20% fall in peak expiratory flow was, however, still higher than before therapy in the cat immunotherapy group (p < 0.01) and had not changed significantly during the follow-up period. In the dog immunotherapy group there was no significant change during or after therapy. Specific IgG4 had decreased, and specific IgE in serum had remained low and was comparable to the levels measured at the end of the study period.
CONCLUSIONS: Five years after stopping immunotherapy, objectively measured bronchial allergen sensitivity had increased and had approached pretreatment conditions. Asthma symptoms, according to patients' subjective evaluations, had continued to be mild in most patients, and bronchial histamine sensitivity had remained stable. These observations could reflect remaining effects of immunotherapy or the natural history of mild asthma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8543744     DOI: 10.1016/s0091-6749(95)70223-7

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  14 in total

Review 1.  [Allergen-specific Immunotherapy for children and adolescents - a review on available products in Austria].

Authors:  Zsolt Szépfalusi; Waltraud Emminger; Franz Eitelberger; Manfred Götz; Andrea Grillenberger; Elisabeth Horak; Isidor Huttegger; Dieter Koller; Helmut Litscher; Rudolf Schmitzberger; Eva-Maria Varga; Josef Riedler
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

Review 2.  Immunotherapy in asthma.

Authors:  J A Douglass; F C Thien; R E O'Hehir
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

Review 3.  Does allergen immunotherapy alter the natural course of allergic disorders?

Authors:  X Yang
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Decision-making analysis for allergen immunotherapy versus nasal steroids in the treatment of nasal steroid-responsive allergic rhinitis.

Authors:  Joshua L Kennedy; Derek Robinson; Jared Christophel; Larry Borish; Spencer Payne
Journal:  Am J Rhinol Allergy       Date:  2014 Jan-Feb       Impact factor: 2.467

5.  The major dog allergens, Can f 1 and Can f 2, are salivary lipocalin proteins: cloning and immunological characterization of the recombinant forms.

Authors:  A Konieczny; J P Morgenstern; C B Bizinkauskas; C H Lilley; A W Brauer; J F Bond; R C Aalberse; B P Wallner; M T Kasaian
Journal:  Immunology       Date:  1997-12       Impact factor: 7.397

Review 6.  Clinical practice: Allergen-specific immunotherapy in children: facts and FAQs.

Authors:  Zsolt Szépfalusi; Saskia Gruber; Thomas Eiwegger; Eleonora Dehlink
Journal:  Eur J Pediatr       Date:  2010-12-10       Impact factor: 3.183

7.  Hyposensitization to allergic reaction in rDer f 2-sensitized mice by the intranasal administration of a mutant of rDer f 2, C8/119S.

Authors:  M Yasue; T Yokota; M Fukada; T Takai; M Suko; H Okudaira; Y Okumura
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

8.  Immunotherapy - Vaccines for allergic diseases.

Authors:  Adrian Young-Yuen Wu
Journal:  J Thorac Dis       Date:  2012-04-01       Impact factor: 2.895

Review 9.  Accelerated immunotherapy schedules.

Authors:  Christopher W Calabria
Journal:  Curr Allergy Asthma Rep       Date:  2013-08       Impact factor: 4.806

10.  Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study.

Authors:  Sabina Rak; William H Yang; Martin R Pedersen; Stephen R Durham
Journal:  Qual Life Res       Date:  2006-10-11       Impact factor: 3.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.